ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
Company Details
- Employees
- 53
- Founded
- 2015
- Address
- 31 Chemin Joseph Aiguier Cs 70071, Marseille,provence-Alpes-Cote D'azur 13009,france
- Phone
- +33 4 13 96 14 90
- Industry
- Biotechnology
- Website
- imchecktherapeutics.com
- Keywords
- antibodies, immuno-oncology, Immune checkpoint Modulators, Auto-immunity, innate immunity, oncology, cancer, precision-based medicine, adaptative immunity, EVICTIONtrial, ICT01, gamma-deltaTcells.
- HQ
- Marseille, Provence-Alpes-Cote d'Azur
Imcheck Therapeutics Questions
Imcheck Therapeutics's helpline number is +33 4 13 96 14 90
Imcheck Therapeutics's website is imchecktherapeutics.com
Imcheck Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/imcheck-therapeutics
Imcheck Therapeutics has
53 employees.
View email and phone details for 53
employees at Imcheck Therapeutics.
Imcheck Therapeutics's industry is
Biotechnology
Imcheck Therapeutics's top competitors are
Sparingvision,
Treefrog Therapeutics,
Phaxiam Therapeutics,
Ose Immunotherapeutics,
Innate Pharma,
Cellectis,
Coave Therapeutics,
Enterome,
Abivax,
Mimabs Sas.
Imcheck Therapeutics's categories are Biotechnology
Imcheck Therapeutics's founding year is 2015
